Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn's disease: A retrospective data analysis in Germany

International Journal of Colorectal Disease

Volumn 20, Issue 1, 2005, Pages 18-23

  Witthöft, Thomas ^a   Ludwig, Diether ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Crohn's disease; Infliximab; Monoclonal; Product surveillance; Tumour necrosis factor

Indexed keywords

AMYLASE; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; LIVER ENZYME; MESALAZINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AMYLASE BLOOD LEVEL; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GERMANY; HUMAN; INTESTINE FISTULA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; RETREATMENT; RETROSPECTIVE STUDY;

ABDOMINAL PAIN; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; GERMANY; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEROIDS; TREATMENT OUTCOME;

EID: 11244254988     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-004-0645-x     Document Type: Article

References (27)

1. Lochs H, Adler G, Beglinger C, Duchmann R, Emmrich J, Ewe K et al (1999) Anti-TNF antibody in Crohn's disease - Status of information, comments and recommendations of an international working group. Z Gastroenterol 37:509-512
2. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA et al (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405
3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al (2002) Maintenance of infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 359:1541-1549
4. Schreiber S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R et al (2001) Use of anti-tumor necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J Colorectal Dis 16:1-11
5. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH et al (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117:761-769
6. Hommes DW, van de Heisteeg BH, van der Spek M, Bartelsman JF, van Deventer SJ (2002) Infliximab treatment for Crohn's disease: One year experience in a Dutch academic hospital. Inflamm Bowel Dis 8:81-86
7. Sample C, Bailey RJ, Todoruk D, Sadowski D, Gramlich L, Milan M et al (2002) Clinical experience with infliximab for Crohn's disease: The first 100 patients in Edmonton, Alberta. Can J Gastroenterol 16:165-170
8. Dotan I, Yeshurun D, Hallak A, Horowitz N, Tiomny E, Reif S et al (2001) Treatment of Crohn's disease with anti TNF alpha antibodies - The experience in the Tel Aviv Medical Center. Harefuah 140:289-293
9. Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH (2001) Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: Is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern Med J 31:146-150
10. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ (2001) Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 96:722-729
11. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters JR, Travers SB, Blank MA, van Deventer SJ (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350:876-885
12. Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM et al (2002) Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 29:667-677
13. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J et al (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346-1352
14. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al (2002) Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 359:1187-1193
15. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. Crohn's disease cA2 Study Group. N Engl J Med 337:1029-1035
16. Stange EF, Schreiber S, Raedler A, Stallmach A, Schoelmerich J, Loeschke K et al (1997) Therapy of Crohn's disease - Results of a consensus conference of the German Society of Digestive and Metabolic Diseases. Z Gastroenterol 35:541-554
17. Bernstein CN, Shanahan F (1996) Purine analogues and Crohn's disease: learning more about the long-term. Gastroenterology 111:1774-1776
18. Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:15552-15563
19. Rovere Querini P, Vecellio M, Sabbadini MG, Ciboddo G (2002) Miliary tuberculosis after biological therapy for rheumatoid arthritis. Rheumatology 41:231
20. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM (2002) Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46:3151-3158
21. Warris A, Bjorneklett A, Gaustad P (2002) Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 344:1099-1100
22. Marotte H, Charrin JE, Miossec P (2001) Infliximab-induced aseptic meningitis. Lancet 358:1784
23. Kashyab AS, Kashyap S (2002) Infliximab-induced aseptic meningitis. Lancet 358:1252
24. Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD, Sandborn WJ, Loftus EV (2002) Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis 8:186-191
25. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ (2004) The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients. Gastroenterology 126:19-31
26. Bernstein C, Blanchard J, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease. Cancer 91:854-862
27. Feagan BG, Enns R, Fedorak RN, Panaccione R, Pare P, Steinhart AH et al (2001) Infliximab for the treatment of Crohn's disease: Efficacy, safety and pharmacoeconomics. Can J Clin Pharmacol 8:188-198